Floyd F. Petersen, a director at Amphastar Pharmaceuticals, Inc. (NASDAQ:), has recently sold shares of the company’s common stock. On June 3, 2024, Petersen parted with 500 shares at an average price of $42.65, totaling over $21,325. The transactions were executed in a range between $42.26 and $42.945, as stated in the regulatory filing. Following the sale, Petersen still owns 78,333 shares of Amphastar Pharmaceuticals.

In addition to the sale, the same filing revealed that Petersen acquired 3,076 restricted stock units (RSUs) on the same day, which will vest on June 3, 2025. These units were granted at no cost to the director. Furthermore, Petersen was awarded a stock option to buy 6,864 shares at a price of $42.25 per share, which also vests on June 3, 2025, and is set to expire on June 3, 2034.

The sale by Petersen was conducted under a Rule 10b5-1 trading plan, which he had adopted on June 13, 2023. Such plans allow company insiders to sell a predetermined number of shares at a predetermined time to avoid accusations of trading on nonpublic information.

Investors and market watchers often pay close attention to insider transactions as they can provide insights into an insider’s view of the company’s future prospects. Amphastar Pharmaceuticals, based in Rancho Cucamonga, California, specializes in pharmaceutical preparations and continues to be a notable player in the healthcare sector.

The transactions were publicly reported in a Form 4 document filed with the Securities and Exchange Commission, which provides details of insider trading activities. Petersen’s recent transactions in Amphastar Pharmaceuticals’ stock demonstrate active management of his investment in the company.

In other recent news, Amphastar Pharmaceuticals has been the subject of considerable attention due to significant developments. The company reported a robust increase in its Q1 2024 financial results, with a 23% rise in net revenue to $171.8 million and a 66% surge in net income to $43.2 million. This growth was primarily driven by strong sales of products like BAQSIMI and Primatene MIST.

Alongside this, the company received FDA approval for its generic inhalation product, AMP-008, a development confirmed by Piper Sandler, which maintained its Overweight rating and a $71.00 stock price target for Amphastar. The approval of AMP-008 is expected to contribute significantly to the company’s revenue due to the limited competition in the market segment of drug/device combinations.

Furthermore, the company outlined plans to launch new products and expressed optimism regarding the approvals of pipeline products such as AMP-002 and the insulin biosimilar AMP-004. The latter presents a sales opportunity of over $4 billion. These are recent developments that underline the company’s growth strategy and its potential for considerable longer-term EBITDA growth.

InvestingPro Insights

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has been exhibiting some intriguing financial metrics and market behavior that could be of interest to investors following insider transactions like those of director Floyd F. Petersen. According to real-time data from InvestingPro, Amphastar boasts a P/E Ratio of 13.25 and a low PEG Ratio of 0.21 for the last twelve months as of Q1 2024, indicating that the stock is trading at a low price relative to near-term earnings growth.

Moreover, the company’s revenue growth has been robust, with a 30.38% increase in the last twelve months as of Q1 2024. This suggests that Amphastar is expanding its financial base, which may be a positive sign for investors looking at the company’s growth potential. Additionally, the firm’s Operating Income Margin stands at a healthy 31.29%, reflecting efficient management and a strong potential for profitability.

An InvestingPro Tip that stands out in the context of insider trading is that management, including directors like Petersen, has been actively buying back shares. This could be interpreted as a signal of confidence in the company’s future performance. Furthermore, another InvestingPro Tip indicates that Amphastar Pharmaceuticals has been profitable over the last twelve months, which could reassure investors about the company’s financial health.

For those interested in a deeper analysis, InvestingPro offers more tips on Amphastar Pharmaceuticals. Currently, there are 11 additional InvestingPro Tips available, which can be accessed through the InvestingPro platform. To enhance your investment research, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

The reported insider transactions, coupled with the company’s solid financial metrics and the insights from InvestingPro, provide a multifaceted view of Amphastar’s position in the market, potentially guiding investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.